** Shares of Insmed INSM.O up 4.6% at $158.34 after reporting better-than-expected quarterly revenue

** Stock on track for fourth straight session of gains and biggest daily percentage jump since December 19

** INSM's quarterly revenue more than doubles to $263.84 million, surpassing analysts' expectations of $171.40 million - data compiled by LSEG

** Posts adj. loss per share of $1.54, greater than estimates of $1.29

** Anticipates up to $1 billion in full-year revenue from its non-cystic fibrosis medication BRINSUPRI, which received approvals from the European Commission in November and the U.S. FDA in August last year

** Average rating of 20 analysts covering INSM is "buy"; median PT is $212

** INSM down ~9% YTD vs. S&P 500 healthcare index's .SPXHC 1% gain

(Reporting by Chibuike Oguh in New York)

((Email: Chibuike.Oguh@thomsonreuters.com; Phone: +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net))